Cargando…
Safety and efficacy of Jujadokseo-hwan for memory deficit (amnesia) in mild neurocognitive disorder: A protocol for randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial
BACKGROUND: Mild neurocognitive disorder (mNCD) is one of the degenerative diseases that results in memory deficit, and can progress to dementia. The effectiveness of drug therapy for mNCD is still debatable, but treatment of this disease has important implications for postponing or preventing demen...
Autores principales: | Jeong, Jin-Hyung, Lee, Ji-Yoon, Kim, Ju-Yeon, Seo, Young-Kyung, Kang, Wee-Chang, Kang, Hyung-Won, Park, So-Jung, Jang, Hye-Kyoung, Park, Yang-Chun, Jung, In Chul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034695/ https://www.ncbi.nlm.nih.gov/pubmed/32080123 http://dx.doi.org/10.1097/MD.0000000000019231 |
Ejemplares similares
-
The effects of herbal medicine (Jujadokseo-hwan) on quality of life in patients with mild cognitive impairment: Cost-effectiveness analysis alongside randomized controlled trial
por: Lee, Ji-Eun, et al.
Publicado: (2023) -
The clinical effects of Gyejibongnyeong-Hwan (Gui Zhi Fu Ling Wan) on patients with hyperlipidemia: A study protocol for a multicenter, double-blind, two-armed parallel, investigator-initiated, exploratory randomized controlled trial
por: Ko, Mi Mi, et al.
Publicado: (2023) -
Investigation of combined treatment of acupuncture and neurofeedback for improving cognitive function in mild neurocognitive disorder: A randomized, assessor-blind, pilot study
por: Jeong, Jin-Hyung, et al.
Publicado: (2021) -
Elucidating the potential pharmaceutical mechanism of Gyejibokryeong-hwan on rosacea using network analysis
por: Kim, Jundong, et al.
Publicado: (2023) -
Multi-center, randomized, double-blind, placebo-controlled, exploratory study to evaluate the efficacy and safety of HAD-B1 for dose-finding in EGFR positive and locally advanced or metastatic NSCLC subjects who need Afatinib therapy: Study protocol clinical trial (SPIRIT Compliant)
por: Park, So-Jung, et al.
Publicado: (2020)